Premium
Maintenance of Remission in antineutrophil cytoplasm antibody‐associated vasculitides
Author(s) -
Guillevin Loïc,
Terrier Benjamin
Publication year - 2019
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.13303
Subject(s) - medicine , anti neutrophil cytoplasmic antibody , giant cell arteritis , vasculitis , rheumatology , microscopic polyangiitis , consensus conference , disease , immunology
The classification of the systemic vasculitides has been controversial for several decades. The Chapel Hill consensus Conference definitions originally developed in 1994, but revised and extended in 2012 are now widely accepted. The American College of Rheumatology ( ACR ) criteria were first published in 1990, are now generally accepted to be out of date and new criteria are needed. More recently the classical division of the ANCA vasculitides using clinical phenotype has come under scrutiny with evidence from epidemiological, genetic and outcome studies that perhaps these conditions should be classified on the basis of ANCA specificity into PR 3‐ ANCA positive and MPO ‐ ANCA positive groups. The traditional distinction between giant cell arteritis and Takayasu arteritis has been questioned and some recent studies of GCA have included patients with only extra‐cranial disease. The Diagnostic and Classification Criteria of Vasculitis study ( DCVAS ) will provide new validated classification criteria for the systemic vasculitides.